AcuraStem

AcuraStem is a biotechnology company advancing neuroscience through patient-based drug discovery. AcuraStem's first small molecule drug candidate, AS-1, for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), will enter clinical trials in early 2021. Following this, the company will focus on patient-based strategies to develop treatments for additional neurodegenerative diseases. AcuraStem leverages advanced cell reprogramming and artificial intelligence technologies to change the standard of care for neurodegenerative diseases through patient-targeted therapies.